Literature DB >> 22813421

Who profits from uncritical acceptance of biased estimates of vaccine efficacy and safety?

Lucija Tomljenovic, Christopher A Shaw.   

Abstract

Mesh：

Substances：

Year:  2012        PMID： 22813421      PMCID： PMC3482043          DOI： 10.2105/AJPH.2012.300837

Source DB:  PubMed          Journal:  Am J Public Health        ISSN： 0090-0036            Impact factor:   9.308


× No keyword cloud information.
  10 in total

1.  No autoimmune safety signal after vaccination with quadrivalent HPV vaccine Gardasil?

Authors:  L Tomljenovic; C A Shaw
Journal:  J Intern Med       Date:  2012-05-24       Impact factor: 8.989

2.  A long story made too short: surrogate variables and the communication of HPV vaccine trial results.

Authors:  Ansgar Gerhardus; Oliver Razum
Journal:  J Epidemiol Community Health       Date:  2010-05       Impact factor: 3.710

3.  Industry-sponsored clinical research: a broken system.

Authors:  Marcia Angell
Journal:  JAMA       Date:  2008-09-03       Impact factor: 56.272

4.  Cost-effectiveness analysis of a quadrivalent human papilloma virus vaccine in Mexico.

Authors:  Luz Myriam Reynales-Shigematsu; Eliane R Rodrigues; Eduardo Lazcano-Ponce
Journal:  Arch Med Res       Date:  2009-08       Impact factor: 2.235

5.  Letter to the editor response to the article of Luisa Lina Villa HPV prophylactic vaccination: the first years and what to expect from now, in press.

Authors:  Jean Pierre Spinosa; Catherine Riva; Jerome Biollaz
Journal:  Cancer Lett       Date:  2011-02-19       Impact factor: 8.679

6.  Pharmaceutical companies' role in state vaccination policymaking: the case of human papillomavirus vaccination.

Authors:  Michelle M Mello; Sara Abiola; James Colgrove
Journal:  Am J Public Health       Date:  2012-03-15       Impact factor: 9.308

Review 7.  Human papillomavirus (HPV) vaccine policy and evidence-based medicine: are they at odds?

Authors:  Lucija Tomljenovic; Christopher A Shaw
Journal:  Ann Med       Date:  2011-12-22       Impact factor: 4.709

8.  Cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands.

Authors:  Inge M C M de Kok; Marjolein van Ballegooijen; J Dik F Habbema
Journal:  J Natl Cancer Inst       Date:  2009-07-01       Impact factor: 13.506

9.  High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up.

Authors:  L L Villa; R L R Costa; C A Petta; R P Andrade; J Paavonen; O-E Iversen; S-E Olsson; J Høye; M Steinwall; G Riis-Johannessen; A Andersson-Ellstrom; K Elfgren; G von Krogh; M Lehtinen; C Malm; G M Tamms; K Giacoletti; L Lupinacci; R Railkar; F J Taddeo; J Bryan; M T Esser; H L Sings; A J Saah; E Barr
Journal:  Br J Cancer       Date:  2006-11-21       Impact factor: 7.640

10.  Reporting bias in drug trials submitted to the Food and Drug Administration: review of publication and presentation.

Authors:  Kristin Rising; Peter Bacchetti; Lisa Bero
Journal:  PLoS Med       Date:  2008-11-25       Impact factor: 11.069
  10 in total
  2 in total

1.  Postural Orthostatic Tachycardia With Chronic Fatigue After HPV Vaccination as Part of the "Autoimmune/Auto-inflammatory Syndrome Induced by Adjuvants": Case Report and Literature Review.

Authors:  Lucija Tomljenovic; Serena Colafrancesco; Carlo Perricone; Yehuda Shoenfeld
Journal:  J Investig Med High Impact Case Rep       Date:  2014-03-18

2.  HPV vaccines and cancer prevention, science versus activism.

Authors:  Lucija Tomljenovic; Judy Wilyman; Eva Vanamee; Toni Bark; Christopher A Shaw
Journal:  Infect Agent Cancer       Date:  2013-02-01       Impact factor: 2.965
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.